Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNX NASDAQ:CUE NASDAQ:EDIT NASDAQ:HUMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$2.06-2.8%$2.44$1.28▼$7.85$226.37M1.31.54 million shs1.02 million shsCUECue Biopharma$0.78-2.7%$0.79$0.45▼$1.99$59.96M1.53253,672 shs82,041 shsEDITEditas Medicine$2.57-3.0%$2.67$0.91▼$4.12$231.09M2.192.85 million shs1.15 million shsHUMAHumacyte$1.55-1.9%$2.14$1.15▼$6.77$245.47M1.94.02 million shs2.38 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon+0.47%-2.30%-10.92%+1.44%-64.31%CUECue Biopharma-3.43%-1.22%-2.29%+21.04%+14.50%EDITEditas Medicine-0.75%-2.93%+2.32%+52.74%-27.99%HUMAHumacyte+3.27%+2.60%-33.33%-41.04%-75.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon2.3847 of 5 stars3.43.00.00.02.22.50.0CUECue Biopharma2.5569 of 5 stars0.05.00.04.73.00.80.6EDITEditas Medicine4.2154 of 5 stars3.14.00.04.31.92.50.6HUMAHumacyte2.5275 of 5 stars3.52.00.00.02.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 2.75Moderate Buy$12.50506.80% UpsideCUECue Biopharma 0.00N/AN/AN/AEDITEditas Medicine 2.23Hold$5.1098.44% UpsideHUMAHumacyte 3.00Buy$9.75529.03% UpsideCurrent Analyst Ratings BreakdownLatest CUE, ANNX, EDIT, and HUMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025HUMAHumacyteBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$3.508/27/2025HUMAHumacyteBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$3.508/18/2025ANNXAnnexonZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/15/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$3.00 ➝ $5.008/15/2025ANNXAnnexonHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.008/13/2025EDITEditas MedicineRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$4.00 ➝ $6.008/12/2025HUMAHumacyteTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $3.508/12/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.008/11/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.007/23/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.007/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$1.81 per shareN/ACUECue Biopharma$9.29M6.45N/AN/A$0.24 per share3.25EDITEditas Medicine$32.31M7.15N/AN/A$0.21 per share12.24HUMAHumacyte$1.57M156.35N/AN/A$0.03 per share51.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$138.20M-$1.29N/AN/AN/AN/A-70.04%-57.67%11/13/2025 (Estimated)CUECue Biopharma-$40.67M-$0.56N/AN/AN/A-469.35%-230.13%-111.16%11/13/2025 (Estimated)EDITEditas Medicine-$237.09M-$2.85N/AN/AN/A-608.88%-200.25%-68.57%11/3/2025 (Estimated)HUMAHumacyte-$148.70M-$0.45N/AN/AN/AN/AN/A-78.26%11/14/2025 (Estimated)Latest CUE, ANNX, EDIT, and HUMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ANNXAnnexon-$0.36-$0.34+$0.02-$0.34N/AN/A8/12/2025Q2 2025CUECue Biopharma-$0.13-$0.09+$0.04-$0.09$2.00 million$2.95 million8/12/2025Q2 2025EDITEditas Medicine-$0.41-$0.63-$0.22-$0.63$1.81 million$3.58 million8/11/2025Q2 2025HUMAHumacyte-$0.15-$0.24-$0.09-$0.24$0.94 million$0.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A5.675.67CUECue Biopharma0.011.601.60EDITEditas MedicineN/A2.772.77HUMAHumacyte2.972.451.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/ACUECue Biopharma35.04%EDITEditas Medicine71.90%HUMAHumacyte44.71%Insider OwnershipCompanyInsider OwnershipANNXAnnexon11.87%CUECue Biopharma10.78%EDITEditas Medicine2.10%HUMAHumacyte5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.89 million96.84 millionOptionableCUECue Biopharma6076.85 million68.56 millionOptionableEDITEditas Medicine23089.92 million88.03 millionOptionableHUMAHumacyte150158.37 million150.30 millionOptionableCUE, ANNX, EDIT, and HUMA HeadlinesRecent News About These CompaniesHumacyte, Inc. (NASDAQ:HUMA) Receives Consensus Rating of "Buy" from AnalystsAugust 28 at 3:10 AM | marketbeat.comHumacyte initiated with an Overweight at BarclaysAugust 27 at 9:33 AM | msn.comHumacyte, Inc. (NASDAQ:HUMA) Receives Consensus Recommendation of "Buy" from AnalystsAugust 26 at 3:11 AM | americanbankingnews.comMonashee Investment Management LLC Buys New Shares in Humacyte, Inc. $HUMAAugust 23, 2025 | marketbeat.comHumacyte (NASDAQ:HUMA) CEO Laura Niklason Sells 591,685 SharesAugust 21, 2025 | insidertrades.com1,049,828 Shares in Humacyte, Inc. $HUMA Acquired by Maven Securities LTDAugust 21, 2025 | marketbeat.comIs It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?August 20, 2025 | zacks.comWall Street Zen Downgrades Humacyte (NASDAQ:HUMA) to SellAugust 19, 2025 | americanbankingnews.comHumacyte (NASDAQ:HUMA) Downgraded by Wall Street Zen to "Sell"August 18, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for Humacyte Q3 Earnings?August 16, 2025 | marketbeat.comFY2029 EPS Estimates for Humacyte Cut by HC WainwrightAugust 15, 2025 | marketbeat.comTD Cowen Cuts Humacyte (NASDAQ:HUMA) Price Target to $3.50August 13, 2025 | marketbeat.comHumacyte (NASDAQ:HUMA) Price Target Cut to $3.00 by Analysts at HC WainwrightAugust 13, 2025 | marketbeat.comHumacyte’s Earnings Call: Progress Amid ChallengesAugust 13, 2025 | msn.comHumacyte Inc. (HUMA) Stock Price Today - WSJAugust 12, 2025 | wsj.comDurham biotech sees stock plunge on slow salesAugust 12, 2025 | bizjournals.comHumacyte, Inc. (NASDAQ:HUMA) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comHumacyte: Cash Burn And A Glacial Launch Overshadow VAC ProgressAugust 12, 2025 | seekingalpha.comD. Boral Capital Reaffirms "Buy" Rating for Humacyte (NASDAQ:HUMA)August 12, 2025 | marketbeat.comHumacyte (NASDAQ:HUMA) Posts Earnings Results, Misses Estimates By $0.09 EPSAugust 12, 2025 | marketbeat.comHumacyte targets over 200 hospital access points for Symvess as VAC approvals surge and cost cuts extend cash runwayAugust 12, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCUE, ANNX, EDIT, and HUMA Company DescriptionsAnnexon NASDAQ:ANNX$2.06 -0.06 (-2.83%) Closing price 04:00 PM EasternExtended Trading$2.06 0.00 (-0.24%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Cue Biopharma NASDAQ:CUE$0.78 -0.02 (-2.66%) Closing price 04:00 PM EasternExtended Trading$0.80 +0.02 (+2.92%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Editas Medicine NASDAQ:EDIT$2.57 -0.08 (-3.02%) Closing price 04:00 PM EasternExtended Trading$2.54 -0.02 (-0.97%) As of 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Humacyte NASDAQ:HUMA$1.55 -0.03 (-1.90%) Closing price 04:00 PM EasternExtended Trading$1.58 +0.03 (+1.94%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access